A
Ambrx Biopharma Inc
NYSE:AMAM
Ambrx Biopharma Inc
NYSE:AMAM
Price:
28 USD
0.07%
Market Closed
Updated:
May 5, 2024
Ambrx Biopharma Inc
Cash from Investing Activities
|
Ambrx Biopharma Inc
Cash from Investing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Ambrx Biopharma Inc
NYSE:AMAM
|
Cash from Investing Activities
-$46.7m
|
CAGR 3-Years
-878%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-76%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Ambrx Biopharma Inc's Cash from Investing Activities?
Cash from Investing Activities
-46.7m
USD
-46.7m
USD
Based on the financial report for Dec 31, 2022, Ambrx Biopharma Inc's Cash from Investing Activities amounts to -46.7m USD.
What is Ambrx Biopharma Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-878%
-878%
Over the last year, the Cash from Investing Activities growth was -1 355%. The average annual Cash from Investing Activities growth rates for Ambrx Biopharma Inc have been -878% over the past three years .
You don't have any saved screeners yet
